Ichim Thomas E, Solano Fabio, Glenn Eduardo, Morales Frank, Smith Leonard, Zabrecky George, Riordan Neil H
Medistem Laboratories Inc, Tempe, Arizona, USA.
J Transl Med. 2007 Jun 27;5:30. doi: 10.1186/1479-5876-5-30.
Autism spectrum disorders (ASD) are a group of neurodevelopmental conditions whose incidence is reaching epidemic proportions, afflicting approximately 1 in 166 children. Autistic disorder, or autism is the most common form of ASD. Although several neurophysiological alterations have been associated with autism, immune abnormalities and neural hypoperfusion appear to be broadly consistent. These appear to be causative since correlation of altered inflammatory responses, and hypoperfusion with symptology is reported. Mesenchymal stem cells (MSC) are in late phases of clinical development for treatment of graft versus host disease and Crohn's Disease, two conditions of immune dysregulation. Cord blood CD34+ cells are known to be potent angiogenic stimulators, having demonstrated positive effects in not only peripheral ischemia, but also in models of cerebral ischemia. Additionally, anecdotal clinical cases have reported responses in autistic children receiving cord blood CD34+ cells. We propose the combined use of MSC and cord blood CD34+cells may be useful in the treatment of autism.
自闭症谱系障碍（ASD）是一组神经发育疾病，其发病率正呈流行趋势，约每166名儿童中就有1名患病。自闭症障碍，即自闭症，是ASD最常见的形式。尽管已有多种神经生理学改变与自闭症相关，但免疫异常和神经灌注不足似乎普遍存在。鉴于炎症反应改变和灌注不足与症状之间存在相关性报道，这些因素似乎具有因果关系。间充质干细胞（MSC）正处于治疗移植物抗宿主病和克罗恩病这两种免疫失调疾病的临床开发后期阶段。已知脐带血CD34+细胞是有效的血管生成刺激剂，不仅在周围缺血模型中，而且在脑缺血模型中都已显示出积极效果。此外，有临床病例报道自闭症儿童接受脐带血CD34+细胞后有反应。我们提出联合使用MSC和脐带血CD34+细胞可能对自闭症治疗有用。
